Clinical Trial Update: Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC [Phase 3]

View source ↗

Summary

A Phase 3 multicenter randomized trial evaluating ADV-TK gene therapy to improve outcomes after liver transplantation for advanced hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• ADV-TK

Snippet

Sponsor: Huazhong University of Science and Technology | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: UNKNOWN